Chronic granulomatous disease (CGD) is a primary immunodeficiency disease symptomized by failure to generate superoxide and recurrent bacterial and fungal infections. Allogeneic bone marrow transplantation (BMT) is one of the therapeutic options available. However, it presents considerable risk to the recipient, especially if the patient is already at an advanced stage of disease, after repeated bacterial and fungal infections and organ damage. We present a case report of a 6-year-old child with long-standing CGD, severe clubbing, and jeopardized pulmonary function after multiple bacterial pulmonary infectious episodes, who had failed treatment with sulphamethazole trimethoprim, multiple antibiotic courses, itraconazole, as well as steroid and interferon-␥ therapy. He underwent allogeneic peripheral blood stem cell transplantation (alloPBSCT) from his HLA-matched MLC non-reactive sister following non-myeloablative conditioning. His ANC did not fall below 0.2 ؋ 10 9 /l, his lowest WBC was 0.6 ؋ 10 9 /l, and his platelets did not fall below 28 ؋ 10 9 /l. He had normal engraftment, with no mucositis or organ toxicity. Neither parenteral nutrition nor platelet infusions were necessary. Partial donor chimerism following alloPBSCT was converted to full donor chimerism and superoxide production reverted to normal after donor lymphocyte infusions (DLI) from his HLA-matched sister. Twenty four months post transplant the patient is well, with stable and durable engraftment, 100% donor chimerism, normal superoxide production, no GVHD, and stabilization of his pulmonary condition. We suggest that alloPBSCT preceded by non-myeloablative conditioning and followed by DLI may constitute a successful
Chronic granulomatous disease (CGD) is a primary immunodeficiency disease caused by the absence of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in the professional phagocytic cells. The lack of NADPH leads to failure to generate superoxide, which is necessary for the killing of micro-organisms, thus rendering the patient liable to recurrent bacterial and fungal infections. [1] [2] [3] [4] CGD is a heterogeneous syndrome caused by a diversity of mutations, and multiple genes are affected, leading to a defect in one of four proteins which are major constituents of the enzyme complex that transfers electrons from NADPH to oxygen, creating microbicidal oxidants. 3, 5, 6 Although treatment and prognosis of CGD patients have improved considerably over the past 30 years, due to increased awareness of the disease, and prompt and aggressive treatment of infections with granulocyte transfusions, lifelong antibiotic prophylaxis and interferon-␥ therapy, death caused by overwhelming and multiple recurrent infections is still a serious threat. 1, [7] [8] [9] Allogeneic bone marrow transplantation is a therapeutic option that has been used in CGD patients since 1976 with varying results. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] However, the procedure continues to be controversial for CGD, as well as other genetic diseases, as it still carries a considerable risk to the recipient, and some physicians feel that it should be restricted to selected, very severe, cases in which prophylactic therapy is problematic. 17, 20 Generally speaking, BMT results in CGD are better when the patient is transplanted in an infection-free interval, before septic foci and irreversible organ damage have occurred. 9, 16 The common notion is that the abnormal host marrow must be completely displaced by adequate doses of myeloablative agents, mainly busulfan and cyclophosphamide, before transplant in order to ensure 100% stable engraftment of the donor's marrow. 9, 19 However, the myeloablative conditioning tends to result in increased organ toxicity, transplant-related complications, morbidity and mortality, especially in CGD patients with recurrent bacterial and fungal infections. 9, 20 We have recently demonstrated that it is possible to achi-eve stable engraftment with minimal transplant-related toxicity using non-myeloablative conditioning for G-CSF mobilized PBSCT in patients with malignant and genetic diseases. 21 We have also shown that where only partial donor chimerism occurs, it is possible to achieve complete chimerism by administration of donor lymphocyte infusions (DLI) after transplantation. [22] [23] [24] We now wish to present the case of a 6-year-old child with CGD, recurrent pulmonary infections, pulmonary disability, and failure to thrive, who underwent alloPBSCT after non-myeloablative conditioning, achieving partial chimerism with no transplant-related toxicity. The child subsequently received DLI, and achieved complete donor chimerism. He is currently 24 months post transplant, with sustained engraftment, 100% donor chimerism, normal superoxide production, stabilization of his pulmonary condition and no signs of GVHD.
Case report
A 6-year-old boy with X-linked CGD was referred to our department for alloPBSCT. His parents were first cousins, and two of his brothers had died of CGD, at the ages of 4 and 6 years, from recurrent infections and atypical TB, respectively. The child was diagnosed at the age of 4 years. He had recurrent bacterial pneumonias, bronchiectasis, and respiratory failure which necessitated oxygen therapy. Chest X-ray and computerized tomography (CT) disclosed widespread lung granulomas (Ͼ2.5 cm). He had failed sulphamethazole trimethoprim, multiple antibiotic courses, itraconazole, steroids, and interferon-␥ therapy. Biopsy of the lung granulomas revealed chronic suppurative granulomatous inflammation with negative staining for TB and PAS, and no growth in bacterial, viral or fungal cultures. Superoxide production was Ͻ5% (nmol/10 6 granulocyte/ min stimulated by phorbol myristate acetate (PMA) 100 ng/ml) and abnormal nitroblue tetrazolium test (NBT) (10%) (PMA stimulation). 25 On admission, the child looked small for his age (weight 16 kg, height 102 cm) and had severe clubbing. There was no tachypnea or dyspnea, and no fever. He had general lymphadenopathy (Ͻ1 cm). Heart: systolic murmur 1/6; lungs: bilateral crepitations and wheezing. He had splenomegaly of 3 cm, and hepatomegaly of 4 cm below the costal margin, with a liver span of 10 cm.
Laboratory examinations
Peripheral blood counts and biochemistry were normal. Chest X-ray and CT scan disclosed hyperdensity and ground glass appearance in both upper lungs, with cystic lesions mainly in the left upper lobe, right upper lobe fibrosis, a small amount of pleural effusion in the right base, and small right pleural calcification. There was mild cardiomegaly. Blood gases. O 2 saturation of 95%. Pulmonary function tests revealed restrictive lung disease with FVC 28% and FEV 1 31% of predicted value. ECG and echocardiogram were normal.
The patient was conditioned with a protocol that consisted of fludarabine (Flu) (Schering, Berlin, Germany) 40 mg/m 2 /day ϫ 6 days from day Ϫ10 to Ϫ5, busulfan (Bu) 4 mg/kg/day ϫ 2 days on days Ϫ7 and Ϫ6, and anti-T lymphocyte globulin (ATG) (Fresenius, Munich, Germany) 10 mg/kg/day ϫ 4 days from day Ϫ4 to Ϫ1. Twenty-four hours later he received 27.8 ϫ 10 8 G-CSF mobilized peripheral blood stem cells/kg from his HLA-matched, MLC non-reactive sister. As GVHD prophylaxis, he received cyclosporin A (3 mg/kg/day) from day Ϫ1. In addition, he received sulphamethazole trimethoprim, itraconazole and ganciclovir prophylaxis. No G-CSF was administered post alloPBSCT. WBC did not fall below 0.6 ϫ 10 9 /l (at day ϩ9 to ϩ11), and ANC were never less than 0.2 ϫ 10 9 /l. Platelets did not fall below 28 ϫ 10 9 /l post alloPBSCT. Engraftment was fast, with WBC Ͼ1 ϫ 10 9 /l on day ϩ15, ANC Ͼ0.5 ϫ 10 9 /l on day ϩ16, and platelets Ͼ50 ϫ 10 9 /l on day ϩ13, and Ͼ100 ϫ 10 9 /l on day ϩ30. The patient did not require any parenteral nutrition or platelet transfusions. There was no mucositis or organ toxicity and, especially worthy of note, no pneumonia or deterioration of the pre-transplant pulmonary findings. There was no sepsis or positive blood cultures, and PCR for CMV was negative.
On day ϩ18 the patient developed grade I-II skin GVHD which responded to a short course of steroid therapy. He was discharged in very good condition on day ϩ28 post transplant.
Chimerism studies of the bone marrow (BM) and peripheral blood (PB) at day of engraftment by amelogenin gene PCR 26 disclosed mixed chimerism. Cytogenetic analysis of BM 4 and 8 weeks post transplant revealed 65% and 70% donor cells (46XX), respectively. In an attempt to achieve full donor chimerism cyclosporin A was stopped and a month later, ie 12 weeks post alloPBSCT, the patient was given 5 ϫ 10 4 peripheral blood lymphocytes from his HLAmatched sibling donor. One month following DLI, the percentage of donor cells in the patient's BM had increased to 75% (46XX, by cytogenetics), and 2 months after DLI it was 80%. Six months following DLI chimerism analyses of both BM and PB cells by cytogenetics and amelogenin gene PCR revealed 100% donor cells (100% 46XX). In parallel, superoxide production reached normal levels (20.6 nmol/10 6 granulocytes/min). The patient is now 24 months post alloPBSCT, in good general condition, with stable engraftment, and 100% donor cells. He has no sign of GVHD, his superoxide production is normal, and his pulmonary condition has stabilized.
Discussion
BMT is an attractive therapeutic option for children with CGD who have a matched sibling donor, the idea being that the CGD granulocytes should be replaced by the normal granulocytes of the donor. However, the procedure carries a considerable risk to the recipient, and some physicians recommend it only in severe cases after all other modes of therapy have failed. 17, 20 In severe advanced CGD, transplant-related complications and mortality are high. 20 Moreover, as the disease progresses, the recurrent infections and chronic inflammation gradually result in mostly irreversible restrictive lung disease, lung and liver fibrosis, and major organ failure, which aggravate the risks involved. 1, 8, 9, 27 To date, about a dozen CGD patients have undergone BMT, with varying results. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In these cases, complications occurring after transplant generally correlated with the severity of the basic disease: patients with recurrent bacterial and fungal infections gradually leading to organ disability had a worse outcome than patients transplanted early on in the course of the disease. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The indication, therefore, is that BMT should preferably be performed early on in the disease, if the procedure-related risks can be reduced.
In most of the reported cases, the pre-BMT conditioning consisted of myeloablative Bu and Cy, the rationale being that complete suppression of the host marrow would allow 100% stable engraftment of the donor cells. However, myeloablative chemotherapy can result in severe organ toxicity, including VOD and pulmonary fibrosis, as well as transplant-related complications, morbidity and mortality, especially in children with severe advanced CGD who are already compromised by organ dysfunction, fibrosis and disability. It may also result in long-term sequelae in these children, including a lower IQ, cataracts, infertility, and growth and developmental retardation. 28 Non-myeloablative conditioning, on the other hand, has been shown to ensure stable and long-term engraftment with minimal transplant-related toxicity in patients with malignant and genetic diseases. 21, [29] [30] [31] The rationale here is that transient maximal immunosuppression achieved by non-myeloablative agents such as Flu and ATG suffices to ensure stable engraftment with partial, if not complete, chimerism and a state of bilateral tolerance. 21 Once this state is achieved, donor alloreactive T cells may be used against residual malignant or genetically abnormal stem cells in order to achieve complete chimerism [22] [23] [24] without megadoses of chemoradiotherapy. DLI has previously been shown by us to convert partial chimerism to full donor chimerism in children with genetic disease, [22] [23] [24] and may also be suitable for increasing engraftment of genetically engineered cells following gene therapy, which has recently been attempted in CGD. 6, 32 This approach is especially suitable for children with genetic diseases, where it has been demonstrated that agents with adequate anti-lymphoid and anti-hematopoietic stem cell activity are necessary in order to achieve complete donor lymphoid and hematopoietic stem cell engraftment. However, since no single chemotherapeutic agent or drug is capable of eliminating both stem cell populations, 33 maximal pre-BMT immunosuppression combined with post-BMT DLI may prove an attractive option.
In this paper, we have presented our use of this approach on a child with advanced CGD, with restrictive lung disease and fibrosis due to recurrent pulmonary infections, in whom the accepted treatments of sulphamethazole trimethoprim, itraconazole and interferon-␥, known to improve prognosis and survival, [34] [35] [36] had failed. The transplant went extremely well, with fast and stable engraftment, partial donor chimerism, minimal transient skin GVHD, and no transplantrelated toxicity. The fact that with the use of non-myeloablative conditioning the patient's ANC never fell below 0.2 ϫ 10 9 /l, may have contributed to the benign course of the transplant. In accordance with our strategy, administration of DLI 12 weeks after alloPBSCT resulted in gradual conversion to full donor chimerism (100% 46XX) within 6 months, and normalization of superoxide production.
We believe that non-myeloablative conditioning prealloPBSCT in conjunction with DLI post alloPBSCT is a promising approach towards increasing the success rate and optimizing BMT in children with CGD and other genetic diseases even at an advanced stage of disease when conventional myeloablative BMT is too risky. It could also be combined with G-CSF administration and multiple granulocyte transfusion, as recently reported by the Oszahim et al. 9 Although CGD is not a widely prevalent disease, this approach should be evaluated in a larger group of patients.
